Clinical Trial

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To assess the efficacy and safety of Alflutinib Mesylate versus Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-12-25; most recent amendment 2025-04-09.
Status change: Enrolling by Invitation → Active, Not Recruiting 2020-01-03
Status change: Not Yet Recruiting → Enrolling by Invitation 2019-07-04
Trial Details
NCT Number NCT03787992
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Enrollment 358 participants
Start Date 2019-05-30
Primary Completion 2021-09-15 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-04-11